1312008-66-4

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-bromo-6-chloro-1H-indazol-1-yl)ethanone is used as an anticancer agent for the treatment of various types of cancer, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstr?m's macroglobulinemia. Its application is based on its ability to inhibit the activity of Bruton's tyrosine kinase (BTK) enzymes, which are involved in the growth and spread of cancer cells. By blocking these enzymes, Ibrutinib can help slow down the progression of the disease and improve patients' survival rates.
Used in Cancer Research:
1-(5-bromo-6-chloro-1H-indazol-1-yl)ethanone is used as a research tool for studying the role of Bruton's tyrosine kinase (BTK) in cancer cell growth and proliferation. Its application in this field aids in the development of new therapeutic strategies and a deeper understanding of the molecular mechanisms underlying cancer progression.
Used in Drug Development:
1-(5-bromo-6-chloro-1H-indazol-1-yl)ethanone is utilized in the development of novel drugs and therapies targeting BTK enzymes and other related pathways. Its application in this industry contributes to the advancement of cancer treatment options and the improvement of patient outcomes.

Upstream product

• 540-80-7 tert.-butylnitrite 
• 30273-47-3 4-bromo-5-chloro-2-methyl aniline 
• 1607828-43-2 N-(4-bromo-5-chloro-2-methylphenyl)-acetamide 
• 108-24-7 acetic anhydride 

Downstream Products

• 1312008-67-5 6-chloro-1H-indazole-5-carbonitrile 
• 1312009-22-5 ethyl 4-[6-chloro-5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]butanoate 
• 1312009-57-6 4-[6-chloro-5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]butanoic acid 
• 1613505-06-8 6-chloro-5-(2-(trifluoromethyl)phenyl)-1H-indazole 

Relevant academic research and scientific papers

Discovery, optimization, and biological evaluation of 5-(2- (trifluoromethyl)phenyl)indazoles as a novel class of transient receptor potential A1 (TRPA1) antagonists

A high throughput screening campaign identified 5-(2-chlorophenyl)indazole compound 4 as an antagonist of the transient receptor potential A1 (TRPA1) ion channel with IC50 = 1.23 μM. Hit to lead medicinal chemistry optimization established the SAR around the indazole ring system, demonstrating that a trifluoromethyl group at the 2-position of the phenyl ring in combination with various substituents at the 6-position of the indazole ring greatly contributed to improvements in vitro activity. Further lead optimization resulted in the identification of compound 31, a potent and selective antagonist of TRPA1 in vitro (IC50 = 0.015 μM), which has moderate oral bioavailability in rodents and demonstrates robust activity in vivo in several rodent models of inflammatory pain.

OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.

OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptor are disclosed.